According to an agreement filed by the U.S. Securities and Exchange Commission on Monday in Manhattan federal court, Ariel Darvasi, a genetics professor at the Hebrew University of Jerusalem, will pay about $854,000. The agreement must be approved by U.S. District Judge Richard Berman.

Lawyers for Darvasi could not immediately be reached for comment. Ofra Ash, a spokeswoman for Hebrew University, confirmed Darvasi is a professor there but said the university would not comment until after the settlement was approved.

The SEC in March charged that Darvasi, of Mevaseret Zion, Israel, and another Israeli, Amir Waldman, made “remarkably timed” purchases of Mobileye shares and call options prior to Intel’s March 13 acquisition of Mobileye.

The SEC said the purchases resulted in about $427,000 of profit for Darvasi and $4.5 million for Waldman, after the announcement caused shares of Mobileye to rise 28.2% in one day. Darvasi’s settlement represents the profit he was accused of making, plus a civil penalty of the same amount.

Get Data Sheet, Fortune’s daily tech newsletter.

According to the SEC, both defendants were connected to Mobileye insiders through the Hebrew University scientific community, which developed Mobileye technology and produced at least 11 Mobileye directors and officers.

Waldman, of Yarqona, Israel, is a self-employed engineer, according to the SEC’s complaint. Gregory Bruch, a lawyer for Waldman, said the claims against his client were still pending and declined to comment further.

According to the SEC, Darvasi began buying Mobileye stock on March 2 after selling 40,000 shares of Teva Pharmaceutical Industries, the only securities in his account.

The SEC said Waldman conducted most of his Mobileye trading in the six weeks before the Intel deal was announced. The trading began the day Intel and Mobileye signed a non-disclosure agreement, and generated a 1,883% return.

Neither Mobileye nor Santa Clara, Calif.-based Intel was accused of wrongdoing.